Table 3.
Indications for Considering the Use of rhPTH(1-84) in Hypoparathyroidisma
| 1. Poor control of the serum calcium (serum corrected calcium (<7.5 mg.dL) or clinical symptomatology |
| 2. Oral calcium supplementation > 2.5 g/d or 1,25-(OH)D > 1.5 mcg/d or 1-alpha vitamin D > 3.0 mcg/d |
| 3. Hypercalciuria, nephrolithiasis, nephrocalcinosis, reduced creatinine clearance or eGFR (<60 mL/min) or increased stone risk by urinary biochemical analysis |
| 4. Hyperphosphatemia or calcium-phosphate product > 55 mg2/dL2 (4.4 mmol2/L2) |
| 5. Gastrointestinal dysfunction resulting from intrinsic disease or after bariatric surgery |
| 6. Reduced quality of life |
aBased on data derived from reference 96.